Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 1061-1066

  Jiang, Lu ^a   Gu, Zhao Hui ^a   Yan, Zi Xun ^a   Zhao, Xia ^a   Xie, Yin Yin ^a   Zhang, Zi Guan ^a   Pan, Chun Ming ^a   Hu, Yuan ^b   Cai, Chang Ping ^b   Dong, Ying ^c   Huang, Jin Yan ^a   Wang, Li ^a   Shen, Yang ^a   Meng, Guoyu ^a   Zhou, Jian Feng ^d   Hu, Jian Da ^e   Wang, Jin Fen ^f   Liu, Yuan Hua ^g   Yang, Lin Hua ^h   Zhang, Feng ⁱ   Wang, Jian Min ^j   Wang, Zhao ^k   Peng, Zhi Gang ^l   Chen, Fang Yuan ^m   Sun, Zi Min ⁿ   Ding, Hao ^o   Shi, Ju Mei ^p   Hue, Jian ^q   Yan, Jin Song ^r   Shi, Jing Yi ^a   Xu, Lan ^a   Li, Yang ^a   Lu, Jing ^a   Zheng, Zhong ^a   Xue, Wen ^a   Zhao, Wei Li ^a,s   Chen, Zhu ^a,s   Chen, Sai Juan ^a,s   more..

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f Department of Geratology   (China)

^g JIANGSU CANCER HOSPITAL   (China)

^h SHANXI MEDICAL UNIVERSITY   (China)

ⁱ BENGBU MEDICAL COLLEGE   (China)

^j SECOND MILITARY MEDICAL UNIVERSITY   (China)

^k CAPITAL MEDICAL UNIVERSITY   (China)

^l GUANGXI MEDICAL UNIVERSITY   (China)

^m SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁿ ANHUI PROVINCIAL HOSPITAL   (China)

^o EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^p TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^q SECOND MILITARY MEDICAL UNIVERSITY   (China)

^r DALIAN MEDICAL UNIVERSITY   (China)

^s French Chinese Laboratory of Genomic and Life Sciences Laboratory of Molecular Pathology   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RNA; STAT PROTEIN; DDX3X PROTEIN, HUMAN; DEAD BOX PROTEIN;

ARID1A GENE; ARTICLE; ASXL3 GENE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DDX3X GENE; EP300 GENE; EPIGENETICS; EXOME SEQUENCING; FEMALE; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MGA GENE; MLL2 GENE; MULTIMODALITY CANCER THERAPY; MUTANT; MUTATIONAL ANALYSIS; MUTATOR GENE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN RNA BINDING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STAT3 GENE; STAT5B GENE; TP53 GENE; TRANSCRIPTION INITIATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY; WILD TYPE; ADULT; AGED; AMINO ACID SEQUENCE; CELL CYCLE; CLINICAL TRIAL; EXOME; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROGNOSIS; T CELL LYMPHOMA; UNIPARENTAL DISOMY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CELL CYCLE; DEAD-BOX RNA HELICASES; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION; UNIPARENTAL DISOMY; YOUNG ADULT;

EID: 84940585535     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3358     Document Type: Article

References (52)

1. Tse, E. & Kwong, Y.L. How I treat NK/T-cell lymphomas. Blood 121, 4997-5005 (2013).
2. Au, W.Y. et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classifcation scheme: a single center experience of 10 years. Ann. Oncol. 16, 206-214 (2005).
3. Suzuki, R. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Semin. Hematol. 51, 42-51 (2014).
4. Suzuki, R. et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann. Oncol. 21, 1032-1040 (2010).
5. Chim, C.S. et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103, 216-221 (2004).
6. Kwong, Y.L. et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and effcacy from the Asia Lymphoma Study Group. Blood 120, 2973-2980 (2012).
7. Lee, J. et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 24, 612-618 (2006).
8. Au, W.Y. et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113, 3931-3937 (2009).
9. Quintanilla-Martinez, L. et al. p53 mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am. J. Pathol. 159, 2095-2105 (2001).
10. Ye, Z. et al. p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type. J. Clin. Pathol. 66, 676-680 (2013).
11. Takahara, M., Kishibe, K., Bandoh, N., Nonaka, S. & Harabuchi, Y. P53, N- and K-Ras, and β-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum. Pathol. 35, 86-95 (2004).
12. Wang, B. et al. Immunohistochemical expression and clinical signifcance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am. J. Hematol. 83, 795-799 (2008).
13. Huang, Y. et al. Gene expression profling identifes emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115, 1226-1237 (2010).
14. Iqbal, J. et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23, 1139-1151 (2009).
15. Karube, K. et al. Identifcation of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 118, 3195-3204 (2011).
16. Huang, Y., de Leval, L. & Gaulard, P. Molecular underpinning of extranodal NK/ T-cell lymphoma. Best Pract. Res. Clin. Haematol. 26, 57-74 (2013).
17. Ng, S.B. et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 118, 4919-4929 (2011).
18. Ng, S.B. et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profling. J. Pathol. 223, 496-510 (2011).
19. Koo, G.C. et al. Janus kinase 3-activating mutations identifed in natural killer/T-cell lymphoma. Cancer Discov. 2, 591-597 (2012).
20. Hoshida, Y. et al. Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China. Cancer Sci. 94, 297-301 (2003).
21. Küçük, C. et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat. Commun. 6, 6025 (2015).
22. Bouchekioua, A. et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28, 338-348 (2014).
23. Kimura, H. et al. Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leuk. Lymphoma 55, 962-963 (2014).
24. Guo, Y. et al. Activated janus kinase 3 expression not by activating mutations identifed in natural killer/T-cell lymphoma. Pathol. Int. 64, 263-266 (2014).
25. Siu, L.L., Wong, K.-F., Chan, J.K. & Kwong, Y.-L. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia: recognition of consistent patterns of genetic alterations. Am. J. Pathol. 155, 1419-1425 (1999).
26. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
27. Ojha, J. et al. Identifcation of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br. J. Haematol. 169, 445-448 (2015).
28. Wu, D.W. et al. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene 33, 1515-1526 (2013).
29. Wu, D.W. et al. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin. Cancer Res. 17, 1895-1905 (2011).
30. Jones, D.T. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105 (2012).
31. Pugh, T.J. et al. Medulloblastoma exome sequencing uncovers subtype-specifc somatic mutations. Nature 488, 106-110 (2012).
32. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
33. Sengoku, T., Nureki, O., Nakamura, A., Kobayashi, S. & Yokoyama, S. Structural basis for RNA unwinding by the DEAD-box protein Drosophila Vasa. Cell 125, 287-300 (2006).
34. Bish, R. & Vogel, C. RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma. Mol. Cells 37, 357-364 (2014).
35. Young, L.S. & Rickinson, A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757-768 (2004).
36. Soto-Rifo, R. & Ohlmann, T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley. Interdiscip. Rev. RNA 4, 369-385 (2013).
37. Küçük, C. et al. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin. Cancer Res. 21, 1699-1711 (2015).
38. Yang, F. , Babak, T., Shendure, J. & Disteche, C.M. Global survey of escape from X inactivation by RNA-sequencing in mouse. Genome Res. 20, 614-622 (2010).
39. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
40. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
41. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
42. Sakata-Yanagimoto, M. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 46, 171-175 (2014).
43. Kumar, P. , Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009).
44. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
45. Choi, Y., Sims, G.E., Murphy, S., Miller, J.R. & Chan, A.P. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 7, e46688 (2012).
46. Yau, C. et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 11, R92 (2010).
47. Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665-1674 (2007).
48. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
49. van Dongen, J.J. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257-2317 (2003).
50. Garbelli, A., Beermann, S., Di Cicco, G., Dietrich, U. & Maga, G. A motif unique to the human DEAD-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication. PLoS ONE 6, e19810 (2011).
51. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
52. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).